Furthermore, HER2-low breast cancer exhibits significant biological heterogeneity compared to HER2-zero breast cancer (IHC 0) in terms of molecular subtypes, gene expression profiles, and clinicopathological characteristics [10, 11]. This evidence concerns the gene ERBB2 and breast cancer.